Case Reports in Infectious Diseases

Case Reports in Infectious Diseases / 2019 / Article

Case Report | Open Access

Volume 2019 |Article ID 9890659 | 2 pages | https://doi.org/10.1155/2019/9890659

Screening for Q Fever during Other Bacterial Endocarditis in Endemic Areas: Our Experience with Three Patients

Academic Editor: Antonella Marangoni
Received01 May 2019
Accepted20 Jun 2019
Published08 Jul 2019

Abstract

Endocarditis is not a usual manifestation of acute Q fever. There is an ongoing debate about the need to screen patients for valvular diseases after acute Q fever. We present, for the first time, three patients with bacterial endocarditis from different aetiologies and a simultaneous diagnosis of acute Q fever. All were treated with prolonged antimicrobial treatment, and none of them developed a persistent Q infection. We suggest screening patients with endocarditis from other aetiologies to Q fever.

1. Introduction

Coxiella burnetii is the aetiology of 1–8% of bacterial endocarditis cases. Endocarditis is the most common form of persistent Q fever worldwide, while the manifestations of acute Q fever are asymptomatic infection, flu-like symptoms, pneumonia, or hepatitis, but not endocarditis [1]. Cases of coinfections of persistent Q infection and other bacteria as the causes of endocarditis were described previously [2, 3], but not coinfections of acute Q fever and other bacterial endocarditis.

2. Case Presentation

A 58-year-old healthy male was admitted to the internal medicine department due to weakness, fever, and night sweats for two months. On physical examination, a systolic heart murmur 3/6 was heard over the left sternal border. Abnormal laboratory findings included leukocytosis of 14,000 per microliter, hemoglobin of 9.9 gr/dL, and C-reactive protein (CRP) of 79 mg/L. Five sets of blood cultures were positive for Streptococcus cristatus, and transesophageal echocardiography (TEE) revealed severe aortic regurgitation with a large vegetation and moderate mitral regurgitation. The patient was treated with intravenous ceftriaxone and gentamicin and was referred to an aortic valve replacement, from which he recovered without complications. An immunofluorescent assay (IFA) for Q fever (methods described by Siegman-Igra et al. [4]) was positive for acute infection (phase II IgM = 100; phase II IgG = 400), and due to his risk factors for a persistent infection, he was treated with doxycycline and hydroxychloroquine, for a year, without adverse events or progression to a persistent infection. Follow-up serologic test results are given in Table 1.


PatientPrevious risk factorsResults of blood culturesPathological echocardiographic findingsSurgeryFirst serology for Q feverDuration of prophylaxisFollow-up serology for Q fever (6–12 months from diagnosis)Follow-up serology for Q fever (3–6 months from end of therapy)

1NoneStreptococcus cristatusSevere aortic regurgitation and a large vegetationAortic valve replacementIgM II-100
IgG II-400
IgM I-negative
IgG I-200
12 monthsIgM II-negative
IgG II-200
IgM I-negative
IgG I-negative
NA

2Aortic valve replacement and aortic composite graftEnterococcus faecalisNoneNAIgM II-negative
IgG II-400
IgM I-negative
IgG I-100
4 months (stopped due to side effects: hyperpigmentation of the gingiva and calves)IgM II-negative
IgG II-100
IgM I-negative
IgG I-negative
IgM II-negative
IgG II-100
IgM I-negative
IgG I-negative

3Mitral valve replacementStreptococcus gordoniiNoneNAIgM II-negative
IgG II-200
IgM I-negative
IgG I-negative
12 monthsIgM II-negative
IgG II-400
IgM I-negative
IgG I-200
IgM II-negative
IgG II-1600
IgM I-negative
IgG I-400

Two similar patients were treated in our hospital. The first was a 72-year-old male with a prosthetic aortic valve, who was admitted due to one month of fever, weight loss, and weakness. He had splenomegaly and a purpuric rash in both legs, mild pancytopenia, and blood cultures that grew Enterococcus faecalis (three sets). TEE was unremarkable, and the patient was treated with intravenous ampicillin and gentamicin for six weeks with a good clinical recovery. The other patient was a 62-year-old male, with a prosthetic mitral valve, who was admitted due to four days of transient diplopia and fever. He had unremarkable physical examination, brain tomography, and TEE. He had elevated CRP of 109 mg/L and mild leukocytosis of 12,500 per microliter. Streptococcus gordonii grew in 9 sets of blood cultures, and he was treated with intravenous penicillin and gentamicin for 6 weeks.

Both of these patients had a 4-fold increase of phase II IgG that confirmed a diagnosis of acute Q fever, and they were treated with doxycycline and hydroxychloroquine for 4 and 12 months, respectively, and both had no clinical or laboratory signs of a persistent infection.

3. Discussion

Diagnosis of acute Q fever is based on serology, and the infection is asymptomatic in half of the cases [1]. Our patients definitely had acute Q infection, but the exact timing of the infection is less clear. We think that our patients have been exposed to the pathogen, with an asymptomatic or mild disease rather than a true coinfection. Since molecular tests from infected valves were not available, this remains a speculation.

Our patients had risk factors for recurrent endocarditis and were offered a prolonged antimicrobial treatment to reduce the risk for a persistent infection [5]. None of them progressed to such an infection. Should clinicians look for Coxiella burnetii in all patients with risk factors for a persistent infection, even when alternative diagnoses exist? This issue was not investigated in valvulopathies, but screening patients who are at high risk for a persistent vascular infection has been described previously and revealed 17% seropositive patients in the Netherlands [6]. Further studies are needed to establish an evidence-based policy.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

References

  1. C. Eldin, C. Mélenotte, O. Mediannikov et al., “From Q fever to Coxiella burnetii infection: a paradigm change,” Clinical Microbiology Reviews, vol. 30, no. 1, pp. 115–190, 2017. View at: Publisher Site | Google Scholar
  2. D. Yahav, I. Kuznitz, S. Reisfeld, N. Eliakim-Raz, and J. Bishara, “Polymicrobial Q fever and enterococcal aortic prosthetic valve endocarditis with aortic root abscess,” Vector-Borne and Zoonotic Diseases, vol. 15, no. 5, pp. 326–328, 2015. View at: Publisher Site | Google Scholar
  3. C. Rovery, B. Granel, J.-P. Casalta, H. Lepidi, G. Habib, and D. Raoult, “Coinfection with Coxiella burnetii in infectious endocarditis,” Clinical Microbiology and Infection, vol. 15, pp. 190-191, 2009. View at: Publisher Site | Google Scholar
  4. Y. Siegman-Igra, O. Kaufman, A. Keysary, S. Rzotkiewicz, and I. Shalit, “Q fever endocarditis in Israel and a worldwide review,” Scandinavian Journal of Infectious Diseases, vol. 29, no. 1, pp. 41–49, 1997. View at: Publisher Site | Google Scholar
  5. M. Million, G. Walter, F. Thuny, G. Habib, and D. Raoult, “Evolution from acute Q fever to endocarditis is associated with underlying valvulopathy and age and can be prevented by prolonged antibiotic treatment,” Clinical Infectious Diseases, vol. 57, no. 6, pp. 836–844, 2013. View at: Publisher Site | Google Scholar
  6. J. C. J. P. Hagenaars, P. C. Wever, A. S. van Petersen et al., “Estimated prevalence of chronic Q fever among Coxiella burnetii seropositive patients with an abdominal aortic/iliac aneurysm or aorto-iliac reconstruction after a large Dutch Q fever outbreak,” Journal of Infection, vol. 69, no. 2, pp. 154–160, 2014. View at: Publisher Site | Google Scholar

Copyright © 2019 Said Younis et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

359 Views | 193 Downloads | 0 Citations
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.